Literature DB >> 26988570

Dramatic Response to Combination Erlotinib and Crizotinib in a Patient with Advanced, EGFR-Mutant Lung Cancer Harboring De Novo MET Amplification.

Justin F Gainor1, Matthew J Niederst2, Jochen K Lennerz3, Ibiayi Dagogo-Jack2, Sara Stevens2, Alice T Shaw2, Lecia V Sequist2, Jeffrey A Engelman2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26988570     DOI： 10.1016/j.jtho.2016.02.021

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  25 in total

1.  Combination MET- and EGFR-directed therapy in MET-overexpressing non-small cell lung cancers: time to move on to better biomarkers?

Authors:  Fernando C Santini; Siddharth Kunte; Alexander Drilon
Journal:  Transl Lung Cancer Res       Date:  2017-06

2.  Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non-Small Cell Lung Cancer.

Authors:  Caroline E McCoach; Collin M Blakely; Kimberly C Banks; Benjamin Levy; Ben M Chue; Victoria M Raymond; Anh T Le; Christine E Lee; Joseph Diaz; Saiama N Waqar; William T Purcell; Dara L Aisner; Kurtis D Davies; Richard B Lanman; Alice T Shaw; Robert C Doebele
Journal:  Clin Cancer Res       Date:  2018-03-29       Impact factor: 12.531

Review 3.  Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors.

Authors:  D Westover; J Zugazagoitia; B C Cho; C M Lovly; L Paz-Ares
Journal:  Ann Oncol       Date:  2018-01-01       Impact factor: 32.976

Review 4.  MET/HGF pathway activation as a paradigm of resistance to targeted therapies.

Authors:  Brian Ko; Tianfang He; Shirish Gadgeel; Balazs Halmos
Journal:  Ann Transl Med       Date:  2017-01

5.  Distinctive targetable genotypes of younger patients with lung adenocarcinoma: a cBioPortal for cancer genomics data base analysis.

Authors:  Helei Hou; Chuantao Zhang; Xiaogai Qi; Lei Zhou; Dong Liu; Hongying Lv; Tianjun Li; Dantong Sun; Xiaochun Zhang
Journal:  Cancer Biol Ther       Date:  2019-10-09       Impact factor: 4.742

6.  Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer.

Authors:  Magda Bahcall; Taebo Sim; Cloud P Paweletz; Jyoti D Patel; Ryan S Alden; Yanan Kuang; Adrian G Sacher; Nam Doo Kim; Christine A Lydon; Mark M Awad; Michael T Jaklitsch; Lynette M Sholl; Pasi A Jänne; Geoffrey R Oxnard
Journal:  Cancer Discov       Date:  2016-09-30       Impact factor: 39.397

Review 7.  The multiple paths towards MET receptor addiction in cancer.

Authors:  Leslie Duplaquet; Zoulika Kherrouche; Simon Baldacci; Philippe Jamme; Alexis B Cortot; Marie-Christine Copin; David Tulasne
Journal:  Oncogene       Date:  2018-03-19       Impact factor: 9.867

Review 8.  Emerging uses of biomarkers in lung cancer management: molecular mechanisms of resistance.

Authors:  Shirin Attarian; Numa Rahman; Balazs Halmos
Journal:  Ann Transl Med       Date:  2017-09

9.  Heterogeneity and Coexistence of T790M and T790 Wild-Type Resistant Subclones Drive Mixed Response to Third-Generation Epidermal Growth Factor Receptor Inhibitors in Lung Cancer.

Authors:  Zofia Piotrowska; Mehlika Hazar-Rethinam; Coleen Rizzo; Brandon Nadres; Emily E Van Seventer; Heather A Shahzade; Inga T Lennes; Anthony J Iafrate; Dora Dias-Santagata; Ignaty Leshchiner; Nicholas A Jessop; Haichuan Hu; Subba R Digumarthy; Rebecca J Nagy; Richard B Lanman; Susan Moody; Matthew J Niederst; Jeffrey A Engelman; Aaron N Hata; Ryan B Corcoran; Lecia V Sequist
Journal:  JCO Precis Oncol       Date:  2018-07-16

10.  Savolitinib ± Osimertinib in Japanese Patients with Advanced Solid Malignancies or EGFRm NSCLC: Ph1b TATTON Part C.

Authors:  Kiyotaka Yoh; Tomonori Hirashima; Hideo Saka; Takayasu Kurata; Yuichiro Ohe; Toyoaki Hida; Anders Mellemgaard; Remy B Verheijen; Xiaoling Ou; Ghada F Ahmed; Manabu Hayama; Ko Sugibayashi; Geoffrey R Oxnard
Journal:  Target Oncol       Date:  2021-05-03       Impact factor: 4.864
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.